

US: 10/796,280
Atty. Docket: CL1510ORD**RECEIVED**
CENTRAL FAX CENTER**OCT 30 2007****AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings of claims in the application.

Listing of claims

1. (Currently amended) A method for identifying a human who has an altered risk for developing coronary stenosis, comprising detecting a single nucleotide polymorphism (SNP) at position 101 of SEQ ID NO: 19350 in a nucleic acid sample from said human, wherein the presence of G at position 101 of SEQ ID NO: 19350 or its complement thereof indicates said human is at an increased risk of developing coronary stenosis, and the presence of A at position 101 of SEQ ID NO: 19350 or its complement thereof indicates said human is at a decreased risk of developing coronary stenosis.

2. - 5. (Canceled)

6. (Original) The method of claim 1 in which detection is carried out by a process selected from the group consisting of: allele-specific probe hybridization, allele-specific primer extension, allele-specific amplification, sequencing, 5' nuclease digestion, molecular beacon assay, oligonucleotide ligation assay, size analysis, and single-stranded conformation polymorphism.

7. - 24. (Canceled)

25. (Previously presented) The method of claim 1, wherein the SNP to be detected is located at position 79090 of SEQ ID NO: 12227.

26. (Previously presented) The method of claim 1, wherein the SNP to be detected is located in the LPA gene.

27. (Previously presented) The method of claim 1, wherein the detection is carried out by using a set of detection reagents comprising the oligonucleotide sequences of SEQ ID NO: 68222, SEQ ID NO: 68223, and SEQ ID NO: 68224.

US: 10/796,280
Atty. Docket: CL1510ORD

28. (Currently amended) A method for identifying a human who has an increased risk for developing coronary stenosis, comprising detecting a single nucleotide polymorphism (SNP) at position 101 of SEQ ID NO: 19350 in a nucleic acid sample from said human, wherein the presence of G at position 101 of SEQ ID NO: 19350 or its complement thereof indicates said human is at an increased risk of developing coronary stenosis.

29. (Previously presented) The method of claim 28 in which detection is carried out by a process selected from the group consisting of: allele-specific probe hybridization, allele-specific primer extension, allele-specific amplification, sequencing, 5' nuclease digestion, molecular beacon assay, oligonucleotide ligation assay, size analysis, and single-stranded conformation polymorphism.

30. (Previously presented) The method of claim 28, wherein the SNP to be detected is located at position 79090 of SEQ ID NO: 12227.

31. (Previously presented) The method of claim 28, wherein the SNP to be detected is located in the LPA gene.

32. (Previously presented) The method of claim 28, wherein the detection is carried out by using a set of detection reagents comprising the oligonucleotide sequences of SEQ ID NO: 68222, SEQ ID NO: 68223, and SEQ ID NO: 68224.

33. (Currently amended) A method for identifying a human who has a decreased risk for developing coronary stenosis, comprising detecting a single nucleotide polymorphism (SNP) at position 101 of SEQ ID NO: 19350 in a nucleic acid sample from said human, wherein the presence of A at position 101 of SEQ ID NO: 19350 or its complement thereof indicates said human is at a decreased risk of developing coronary stenosis.

34. (Previously presented) The method of claim 33 in which detection is carried out by a process selected from the group consisting of: allele-specific probe hybridization, allele-specific primer extension, allele-specific amplification, sequencing, 5' nuclease digestion,

US: 10/796,280
Atty. Docket: CL1510ORD

molecular beacon assay, oligonucleotide ligation assay, size analysis, and single-stranded conformation polymorphism.

35. (Previously presented) The method of claim 33, wherein the SNP to be detected is located at position 79090 of SEQ ID NO: 12227.

36. (Previously presented) The method of claim 33, wherein the SNP to be detected is located in the LPA gene.

37. (Previously presented) The method of claim 33, wherein the detection is carried out by using a set of detection reagents comprising the oligonucleotide sequences of SEQ ID NO: 68222, SEQ ID NO: 68223, and SEQ ID NO: 68224.